Gland Pharma share price hits 52-week high as Q4 profit nearly doubles, dividend announcement

The stock rose as much as 14.32% to ₹2,135.9 apiece, its 52-week-high level, on the National Stock Exchange. At 9:52 am, it was up 12.59% to ₹2,103.50 per unit.

The scrip had hit its 52-week low of ₹1,452.20 on May 19, 2025.

Gland Pharma Q4 results

The company reported a 96.56% increase in its consolidated profit after tax to ₹366.67 crore in the latest March quarter, compared to ₹186.54 crore in the year-ago period.

Its revenue from operations advanced 22.30% to ₹1,742.79 crore in Q4 FY26 as against ₹1,424.90 crore in the corresponding period of the previous fiscal year.

The company said that the revenue growth was backed by an increase in capacity and new product ramp-ups. Contract and pricing renegotiations, cost reduction steps and operating leverage helped the margin profile, it added.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) saw an uptick of 48% to ₹513 crore in the quarter under review vs ₹347.5 crore in Q4 FY25, according to an exchange filing. The EBITDA margin stood at 29% vs 24%.

The company also recommended a final dividend of ₹20 per share for the financial year 2025-26, subject to approval by the shareholders at the ensuing Annual General Meeting (AGM). The record date is August 11.

Commenting on earnings, Srinivas Sadu, Executive Chairman of Gland Pharma, stated, "Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses, including Cenexi."

"The 38% adjusted EBITDA margin of the base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing cost efficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships," he added.